StageZero Life Sciences Valuation

Is 61N1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 61N1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 61N1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 61N1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 61N1?

Key metric: As 61N1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 61N1. This is calculated by dividing 61N1's market cap by their current revenue.
What is 61N1's PS Ratio?
PS Ratio	1.2x
Sales	US$2.99m
Market Cap	US$3.63m

61N1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	-1.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 61N1's PS Ratio compare to its peers?

The above table shows the PS ratio for 61N1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.1x
CNW co.don	0.7x	n/a	€6.5m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
MDG1 Medigene	3x	16.1%	€22.5m
ECX Epigenomics	8.4x	n/a	€1.1m
61N1 StageZero Life Sciences	1.2x	n/a	€4.9m

Price-To-Sales vs Peers: 61N1 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does 61N1's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.1x	21.8%
61N1 StageZero Life Sciences	1.2x	n/a	US$3.63m
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	8.1x	42.4%
61N1 StageZero Life Sciences	1.2x	n/a	US$3.63m

No more companies

Price-To-Sales vs Industry: 61N1 is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Biotechs industry average (10.2x).

Price to Sales Ratio vs Fair Ratio

What is 61N1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

61N1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 61N1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%